Management of Gouty Arthritis Flare in HFrEF Patients with Allopurinol

Initiating Allopurinol During Active Flare

The American College of Rheumatology recommends starting urate-lowering therapy during the flare, as delaying treatment offers no clinical benefit, particularly in high-risk comorbidities like HFrEF 1
The European League Against Rheumatism guidelines identify ischemic heart disease, which commonly coexists with HFrEF, as a factor associated with increased risk of recurrent severe flares, making early treatment crucial 2

The American College of Rheumatology recommends starting with ≤100 mg/day in patients with normal renal function, and even lower doses (≤50 mg/day) if CKD stage ≥3 is present 1, 3
Increase by 100 mg increments every 2-4 weeks until serum uric acid target is achieved, with a target serum uric acid <6 mg/dL (360 μmol/L) for maintenance 1, 2, 5

The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis when initiating allopurinol, regardless of whether starting during or after a flare, with colchicine 0.6 mg daily as the preferred first-line prophylactic agent 1, 3
Low-dose corticosteroids (prednisone/prednisolone) may be the safest option in HFrEF patients, particularly if concurrent CKD exists, as NSAIDs carry significant cardiovascular and renal risks 1, 4

The American College of Rheumatology recommends corticosteroids as the preferred acute treatment in HFrEF patients due to the contraindications of NSAIDs (fluid retention, renal dysfunction, heart failure exacerbation) 1
Colchicine can be used for acute treatment if not contraindicated by renal function, but requires dose adjustment in CKD 1

The American College of Rheumatology and the European League Against Rheumatism guidelines advise against delaying allopurinol initiation waiting for flare resolution, as this offers no benefit and delays definitive treatment in a high-risk patient 1, 2
The American College of Rheumatology recommends against starting at 300 mg/day, as this significantly increases hypersensitivity risk, particularly with any degree of renal impairment 1
The American College of Rheumatology advises against using NSAIDs for flare treatment or prophylaxis in HFrEF, due to the cardiovascular and renal risks outweighing benefits 1